The impact of baseline visual acuity on the treatment outcomes in patients treated with AflIbercept in real-life clinical setting (INSIGHT)
The study will assess the mean change in Visual Acuity (VA) (overall and stratified by baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting.
In addition, the study will ascertain the baseline VA in treatment –naïve Wet Age-Related Macular Degeneration or neo-vascular AMD (wAMD) patients who start treatment with Aflibercept in a real-life setting and it will assess the impact of baseline VA on the outcomes of Aflibercept treatment.
-Treatment-naïve eyes with neovascularization AMD, with the indication to be treated with Aflibercept. One and/or two eyes per patient.
-Eyes treated previously with another anti-VEGF drug.
E-mail: [email protected]
Phone: (+)1-888-84 22937
INSIGHT – The Impact of baseliNe viSual acuity on the treatment outcomes in patients treated with AflIbercept in real-life clinical settinG. Analysis of data from the SwedisH Macula RegisTer